NLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience(R) Phase 2a Clinical Trial for Patients with Narcolepsy

Since the interim results were released in March, patient enrollment has nearly doubled Of the 60 patients planned for the study, 54 have now been randomized with several others currently undergoing screening Nearly 90% of patients that completed the